The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Aggressive margin reduction with MRI-guided stereotactic body radiotherapy (SBRT) led to a significantly lower incidence of late genitourinary and gastrointestinal toxicities at 2 years compared with ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

SBRT administered to oligometastases was associated with survival benefits in phase 2 trial participants with CRPC receiving abiraterone and ADT. For patients with oligometastatic castrate-resistant ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after ...

Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting ...

Stereotactic body radiotherapy (SBRT) is a safe treatment option for patients with oligometastatic cancer, with only 0.5% of patients experiencing severe acute toxicities within 6 months, according to ...